SHYNDEC(SH:600420) Ge Long Hui A P P·2026-02-09 08:34Core Viewpoint - China National Pharmaceutical Group Modern (国药现代) announced that its wholly-owned subsidiary, China National Pharmaceutical Industry Co., Ltd. (国药工业), has received a GMP compliance inspection notice for its Langfang branch, indicating that the production line for lyophilized powder injection has passed the GMP compliance check [1] Group 1: GMP Compliance Inspection - The GMP compliance inspection scope covered the lyophilized powder injection production line at the Langfang branch of China National Pharmaceutical Industry [1] - The production line is newly built, with a total investment of approximately RMB 92.8277 million (unaudited) [1] - The successful compliance check indicates that the new production line meets the requirements of the "Good Manufacturing Practice for Pharmaceutical Products (2010 Revision)" [1] Group 2: Market Implications - The approval of the lyophilized powder injection production line is expected to help the company stabilize and increase the production capacity of its anesthesia and analgesia product segment to meet market demand [1] - The recent developments are not expected to have a significant impact on the company's current operating performance [1]